Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EFE-P100 + docetaxel
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Transdermal (EFE-P100, Device Patches), Intravenous (docetaxel)
01
Overview
EFE-P100 + docetaxel is an investigational combination therapy comprising the use of the tumor treating fields (TTFields) device EFE-P100 and the chemotherapy agent docetaxel. EFE-P100 is a non-invasive medical device that generates alternating electric fields at specific frequencies and intensities to disrupt mitosis and inhibit tumor cell division. Docetaxel is a taxane-based chemotherapeutic agent that stabilizes microtubules, leading to cell cycle arrest and apoptosis. This combination is studied for use in stage IV non-small cell lung cancer (NSCLC) patients who have progressed following platinum-based chemotherapy and anti-PD-1/PD-L1 antibody treatment[1][3][7]. The principal rationale is that simultaneous inhibition of cell division by alternating electric fields and cytotoxic chemotherapy may result in enhanced antitumor efficacy.
- Other names
- tumor treating fields EFE-P100 + docetaxel
02
Targets
PXR (Pregnane X receptor)BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on EFE-P100 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EFE-P100 + docetaxel.